UPDATE: Maxim Group Assumes Cardiff Oncology (CRDF) at Buy

Maxim Group analyst Naureen Quibria assumes coverage on Cardiff Oncology (NASDAQ: CRDF) with a Buy rating and a price target of $20.00.

The analyst comments "Onvansertib is a pipeline drug that offers long-term growth opportunities. Cardiff’s PLK inhibitor, onvansertib, has ongoing studies in several metastatic cancers in combination with standard of care: in colorectal cancer patients with KRAS mutations (mCRC), in castration-resistant prostate cancer (mCRPC), and another recently initiated in pancreatic ductal adenocarcinoma (mPDAC)."

For an analyst ratings summary and ratings history on Cardiff Oncology click here. For more ratings news on Cardiff Oncology click here.

Shares of Cardiff Oncology closed at $5.76 yesterday.

You May Also Be Interested In

• Barclays Starts SK Hynix (SKHY) at Overweight
• Susquehanna Downgrades Canadian National Railway (CNI) to Neutral
• Goldman Sachs on Conviction List Buy rated Wells Fargo (WFC): 'We expect a modestly positive investor response'